HEYL is a family-owned pharmaceutical company that specializes in the development, manufacturing, and distribution of CBRN Medical Countermeasures. Founded in 1926 in Berlin, Germany, HEYL has grown into a global leader for the treatment of patients following a radiological or nuclear incident. Today, HEYL is active across the full CBRN threat spectrum, offering medical countermeasures and related products to respond to chemical and biological threats, in addition to its radiological and nuclear portfolio.
HEYL’s presence in Japan dates back to 1972. In 1983 the company established Heyl Japan K.K.. Currently HEYL holds three PMDA approvals for products used in the treatment internal radiological contamination.